Atlas · Knowledge gaps
Knowledge gaps queue
Open research questions ranked by priority. Each gap is a candidate for a debate or a SPEC-033 bounty challenge.
5
open gaps
| # | Title | Status | Priority | Domain | Created | |
|---|---|---|---|---|---|---|
| 1 | How do NTN1+ endothelial cells specifically target and communicate with regener… While the study demonstrates that NTN1+ECs foster axon regeneration and form vascular niches, the specific cell-cell communication mechanisms and targeting sign… gap-pubmed-20260410-142337-ff7f045d | open | 0.800 | peripheral nerve regeneration | 2026-04-10 | Open → |
| 2 | Which specific bioactive compounds in QZP are responsible for BDNF/TrkB/CREB pa… QZP is a multi-component herbal formula, but the study doesn't identify which specific compounds drive the observed neuroprotective effects. Understanding the a… gap-pubmed-20260410-165543-fdfd7411 | open | 0.800 | peripheral nerve regeneration | 2026-04-10 | Open → |
| 3 | What molecular mechanisms control let-7a-5p downregulation in NTN1+ endothelial… The study identifies low let-7a-5p expression in NTN1 EC-EXO as critical for niche formation, but the regulatory mechanisms controlling this microRNA's selectiv… gap-pubmed-20260410-142337-1e53429e | open | 0.790 | peripheral nerve regeneration | 2026-04-10 | Open → |
| 4 | How does QZP treatment compare to established BDNF-based therapies for peripher… The study demonstrates QZP activates BDNF signaling but doesn't compare its efficacy to direct BDNF administration or other established neurotrophic treatments.… gap-pubmed-20260410-165543-93997f07 | open | 0.750 | peripheral nerve regeneration | 2026-04-10 | Open → |
| 5 | What is the optimal treatment duration and dosing regimen for QZP in facial ner… The study used a fixed 14-day treatment protocol with single dose level, but doesn't establish dose-response relationships or optimal treatment windows. This li… gap-pubmed-20260410-165543-043516d9 | open | 0.720 | peripheral nerve regeneration | 2026-04-10 | Open → |